Download App

Log in to access Online Inquiry
Company Overview More
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
CEO: Houston Ph.D., John G.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > ARVN Arvinas > Detailed Quotes

ARVN Arvinas

44.140+1.300+3.03%
Trading Session 05/19 14:35 ET
High
44.290
Open
42.500
Turnover
7.45M
Low
41.890
Pre Close
42.840
Volume
172.57K
Market Cap
2.35B
P/E(TTM)
Loss
52wk High
108.465
Shares
53.17M
P/E(Static)
Loss
52wk Low
37.410
Float Cap
1.95B
Bid/Ask %
50.00%
Historical High
108.465
Shs Float
44.11M
Volume Ratio
0.46
Historical Low
10.190
Dividend TTM
--
Div Yield TTM
35
P/B
3.24
Dividend LFY
--
Div Yield LFY
79.29%
Turnover Ratio
0.39%
Amplitude
5.60%
Avg Price
43.182
Lot Size
1
Float Cap
1.95B
Bid/Ask %
50.00%
Historical High
108.465
Shs Float
44.11M
Volume Ratio
0.46
Historical Low
10.190
Dividend TTM
--
P/B
3.24
Dividend LFY
--
Turnover Ratio
0.39%
Amplitude
5.60%
Avg Price
43.182
Lot Size
1
Price Forecast

No Data

News

Comment